Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Talzenna talazoparib Metastatic castration-resistant prostate cancer (mCRPC) Suspended
Nurtec ODT rimegepant Migraine, prevention Withdrawn
Eylea HD aflibercept 8mg/0.07mL macular degeneration, age related Active
Uplizna inebilizumab Neuromyelitis optica spectrum disorders (NMOSD) Active
Eylea HD aflibercept 8mg/0.07mL diabetic macular edema Active
N/A everolimus Renal angiomyolipoma associated with tuberous sclerosis Active
N/A panitumumab Left-sided metastatic colorectal cancer (mCRC) Active
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
N/A Nab-paclitaxel Solid tumours Active
Velsipity etrasimod Ulcerative colitis Active